However, not all solutions are created equal, and what works for one person may not work for another
Baseline A1c was 7.57% and the placebo-adjusted A1c reductions were 0.36% and 0.41% with sotagliflozin 200 and 400 mg, respectively, at 24 weeks and 0.25% and 0.31% at 52 weeks (all P 30 mL/min/1.73 m 2 but 10-fold increase in GLP-1, which can delay gastric emptying and increase satiety
The study was randomized, double-blinded, and placebo-controlled with 22 healthy males who had high plasma urate levels
Beyond SELECT's findings in people without diabetes, semaglutide has demonstrated cardiovascular benefits across diverse patient populations, including those with type 2 diabetes and varying degrees of heart failure
The review includes conventional treatments that are often covered on other websites, some integrative therapies that may offer potential benefit, and a couple of alternative therapies that pose some risk